» Articles » PMID: 28469510

A Study of Use of "PORT" Catheter in Patients with Cancer: A Single-Center Experience

Overview
Publisher Sage Publications
Specialty Oncology
Date 2017 May 5
PMID 28469510
Citations 10
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Effective and reliable venous access is one of the cornerstones of modern medical therapy in oncology.

Materials And Methods: This is a prospective observational study, which collected data of patients who require "PORT" catheter insertion for any cancer, at a tertiary care oncology hospital in Ahmadabad, Gujarat, India, during a 2-year period.

Aims And Objectives: The main objective of this study was to study the various complications and outcomes related to "PORT" catheters.

Results: "PORT" catheter was inserted in 100 patients and was most commonly used in solid malignancies (n = 86, 86%), followed by hematologic malignancies (n = 14, 14%). Among the solid malignancies, breast cancer (38, 38%) was the most common underlying disease, whereas among the hematologic malignancies, acute lymphoblastic leukemia (6, 6%) was the most common underlying disease for "PORT" catheter insertion. Chemotherapy was started on the first day of "PORT" catheter in 74% of patients in the "PORT" study group. The various complications developed in the "PORT" study group in the descending order are as follows: 4 patients (4%) developed early infection (⩽30 days after "PORT" placement), 4 (4%) late infection (⩾30 days after "PORT" placement), 4 (4%) bloodstream infection, 2 (2%) local skin infection at the "PORT" insertion site, 2 (2%) dislodgment of the "PORT" catheter, 2 (2%) fracture of the "PORT" catheter, and 1 recurrent pleural effusion. One patient (1%) developed thrombosis as the complication of "PORT" catheter insertion.

Conclusions: The most disturbing aspect of treatment for a patient with cancer is multiple painful venipunctures made for administration of cytotoxic agents, antibiotics, blood products, and nutritional supplements. The focus of this prospective observational research is to study the various underlying diseases for which "PORT" catheter is needed in different solid and hematologic malignancies and the various complications and outcomes in pediatric and adult patients with cancer.

Citing Articles

Correlation between increased flushing intervals and malfunction and infectious complications in fully implantable catheters during the COVID-19 pandemic.

Esteves A, Pimenta de Figueiredo V, Saes G, Zerati A, Puech-Leao P, Wolosker N Einstein (Sao Paulo). 2024; 22:eAO0736.

PMID: 39661853 PMC: 11634335. DOI: 10.31744/einstein_journal/2024AO0736.


Exploring factors associated with failure of totally implanted vascular access devices in a regional and rural health service: a retrospective case-control study.

Meredith C, Mander G, Thompson M, Elliott J, Reynolds L, Ng L BMJ Open Qual. 2024; 13(3).

PMID: 39117394 PMC: 11409290. DOI: 10.1136/bmjoq-2024-002799.


Central venous access device terminologies, complications, and reason for removal in oncology: a scoping review.

Curtis K, Gough K, Krishnasamy M, Tarasenko E, Hill G, Keogh S BMC Cancer. 2024; 24(1):498.

PMID: 38641574 PMC: 11027380. DOI: 10.1186/s12885-024-12099-8.


Predictors of central line-associated bloodstream infections in cancer patients undergoing chemotherapy through implanted venous access ports: a retrospective, observational study.

Chen H, Yamane T, Haruyama T, Ishihara M, Kazahari H, Sakamoto T Transl Cancer Res. 2024; 12(12):3538-3546.

PMID: 38192991 PMC: 10774051. DOI: 10.21037/tcr-23-1217.


Correlations between activation, family adaptation, and self-perceived burden in breast cancer patients with an implanted venous access port: A cross-sectional study.

Li K, Zhu L, Zhang L Medicine (Baltimore). 2023; 102(50):e36443.

PMID: 38115378 PMC: 10727680. DOI: 10.1097/MD.0000000000036443.


References
1.
Schiffer C, Mangu P, Wade J, Camp-Sorrell D, Cope D, El-Rayes B . Central venous catheter care for the patient with cancer: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol. 2013; 31(10):1357-70. DOI: 10.1200/JCO.2012.45.5733. View

2.
Kumar A, Srinivasan N, Thakkar J, Mathew S . A prospective observational study of the outcome of central venous catheterization in 100 patients. Anesth Essays Res. 2015; 7(1):71-5. PMC: 4173489. DOI: 10.4103/0259-1162.114000. View

3.
Iannacci L, Piomelli S . Supportive care for children with cancer. Guidelines of the Childrens Cancer Study Group. Use of venous access lines. Am J Pediatr Hematol Oncol. 1984; 6(3):277-81. View

4.
Heibl C, Trommet V, Burgstaller S, Mayrbaeurl B, Baldinger C, Koplmuller R . Complications associated with the use of Port-a-Caths in patients with malignant or haematological disease: a single-centre prospective analysis. Eur J Cancer Care (Engl). 2009; 19(5):676-81. DOI: 10.1111/j.1365-2354.2009.01115.x. View

5.
Schwarz R, Groeger J, Coit D . Subcutaneously implanted central venous access devices in cancer patients: a prospective analysis. Cancer. 1997; 79(8):1635-40. View